A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, dose-escalation ,and multidose study, aiming to investigate
the safety, tolerability and pharmacokinetics of Gimatecan in Advanced Ovarian Epithelial
Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. To explore the dose-limiting
toxicity (DLT) and the maximum tolerable dose (MTD) of oral administration of Gimatecan
capsules 5 consecutive days, every 28 days.